Literature DB >> 9306579

Immunohistochemical expression of bcl-2 protein in squamous cell carcinoma and basaloid carcinoma of the esophagus.

N Koide1, S Koike, W Adachi, J Amano, N Usuda, T Nagata.   

Abstract

In the present study, the expression of bcl-2 protein in esophageal squamous cell carcinoma (SCC) and basaloid carcinoma (BC) was immunohistochemically examined, and its relation to tumor progression and postoperative survival was determined in SCC. A total of 42 SCC and 4 BC tumor samples were fixed with formalin, embedded in paraffin, and stained using monoclonal bcl-2 protein antibody, clone 124. Immunoreactivity was semiquantitatively scored, and the staining results were compared with the pathologic features and survival rates. The cytoplasm of basal cells from the normal esophageal epithelium was stained. In some well- and moderately differentiated SCCs, bcl-2 protein-positive reaction was observed in the peripheral part of the tumor cord, but in poorly differentiated SCC, the cells were weakly or hardly stained. However, in BC, the cells were strongly stained. The immunoreactivity was positive in 45.2% of the SCCs and all of the BCs. There were no significant differences in pathological features or patient survival between the bcl-2 protein-positive and protein-negative SCCs. In conclusion, the expression was not related to tumor progression and had no prognostic significance in SCC. Conversely, BC had strong immunohistochemical expression, probably associated with the differentiation of carcinoma cells simulating the basal cells of the esophagus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9306579     DOI: 10.1007/BF02384977

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.540


  27 in total

1.  Carcinoma of the esophagus; a review of 381 cases admitted to Toronto General Hospital, 1937-1953 inclusive.

Authors:  O IBBERSON; R A MUSTARD
Journal:  Ann Surg       Date:  1956-12       Impact factor: 12.969

2.  bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma.

Authors:  J J Yunis; M G Mayer; M A Arnesen; D P Aeppli; M M Oken; G Frizzera
Journal:  N Engl J Med       Date:  1989-04-20       Impact factor: 91.245

3.  Basaloid-squamous carcinoma of the esophagus with marked deposition of basement membrane substance.

Authors:  K Takubo; K Mafune; Y Tanaka; T Miyama; K Fujita
Journal:  Acta Pathol Jpn       Date:  1991-01

4.  BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death.

Authors:  D M Hockenbery; M Zutter; W Hickey; M Nahm; S J Korsmeyer
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

5.  Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells.

Authors:  D L Vaux; S Cory; J M Adams
Journal:  Nature       Date:  1988-09-29       Impact factor: 49.962

6.  Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers.

Authors:  M Colombel; F Symmans; S Gil; K M O'Toole; D Chopin; M Benson; C A Olsson; S Korsmeyer; R Buttyan
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

7.  Antigen retrieval technique utilizing citrate buffer or urea solution for immunohistochemical demonstration of androgen receptor in formalin-fixed paraffin sections.

Authors:  S R Shi; B Chaiwun; L Young; R J Cote; C R Taylor
Journal:  J Histochem Cytochem       Date:  1993-11       Impact factor: 2.479

8.  The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status.

Authors:  C Doglioni; A P Dei Tos; L Laurino; C Chiarelli; M Barbareschi; G Viale
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

9.  Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma.

Authors:  M Seto; U Jaeger; R D Hockett; W Graninger; S Bennett; P Goldman; S J Korsmeyer
Journal:  EMBO J       Date:  1988-01       Impact factor: 11.598

10.  Expression of tumour-suppressor gene Rb, apoptosis-suppressing protein Bcl-2 and c-Myc have no independent prognostic value in renal adenocarcinoma.

Authors:  P Lipponen; M Eskelinen; K Syrjänen
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

View more
  4 in total

1.  Recurrence and survival predictive value of phenotypic expression of Bcl-2 varies with tumor stage of colorectal adenocarcinoma.

Authors:  Chakrapani Chatla; Nirag C Jhala; Venkat R Katkoori; Dominik Alexander; Sreelatha Meleth; William E Grizzle; Upender Manne
Journal:  Cancer Biomark       Date:  2005       Impact factor: 4.388

2.  Expression of Bcl-2 and amplification of c-myc are frequent in basaloid squamous cell carcinomas of the esophagus.

Authors:  M Sarbia; C Loberg; M Wolter; J Arjumand; H Heep; G Reifenberger; H E Gabbert
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

3.  Metastatic basaloid-squamous cell carcinoma of the esophagus treated by 5-fluorouracil and cisplatin.

Authors:  Yoshihiro Shibata; Eishi Baba; Hiroshi Ariyama; Ryusuke Miki; Nobumichi Ogami; Shuji Arita; Baoli Qin; Hitoshi Kusaba; Kenji Mitsugi; Hirokazu Noshiro; Takashi Yao; Shuji Nakano
Journal:  World J Gastroenterol       Date:  2007-07-14       Impact factor: 5.742

4.  Correlation of STAT1 with apoptosis and cell-cycle markers in esophageal squamous cell carcinoma.

Authors:  Ying Zhang; Yaozhong Zhang; Hailong Yun; Raymond Lai; Min Su
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.